Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more
Moderna Inc (MRNA) - Total Liabilities
Latest total liabilities as of December 2025: $3.69 Billion USD
Based on the latest financial reports, Moderna Inc (MRNA) has total liabilities worth $3.69 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Moderna Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Moderna Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Moderna Inc Competitors by Total Liabilities
The table below lists competitors of Moderna Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Corpay Inc
NYSE:CPAY
|
USA | $22.19 Billion |
|
Swedbank AB (publ)
PINK:SWDBF
|
USA | $2.84 Trillion |
|
China Telecom Corp Ltd
SHG:601728
|
China | CN¥410.82 Billion |
|
BrightSpring Health Services, Inc. Tangible Equity Unit
NASDAQ:BTSGU
|
USA | $4.23 Billion |
|
Pure Storage Inc
NYSE:PSTG
|
USA | $2.82 Billion |
|
Zoom Video Communications Inc
NASDAQ:ZM
|
USA | $2.10 Billion |
|
KONE Oyj
PINK:KNYJF
|
USA | $6.23 Billion |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
China | CN¥9.05 Trillion |
Liability Composition Analysis (2014–2025)
This chart breaks down Moderna Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Moderna Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Moderna Inc (2014–2025)
The table below shows the annual total liabilities of Moderna Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.69 Billion | +13.79% |
| 2024-12-31 | $3.24 Billion | -29.11% |
| 2023-12-31 | $4.57 Billion | -32.12% |
| 2022-12-31 | $6.74 Billion | -36.00% |
| 2021-12-31 | $10.52 Billion | +120.35% |
| 2020-12-31 | $4.78 Billion | +1051.92% |
| 2019-12-31 | $414.61 Million | -4.00% |
| 2018-12-31 | $431.91 Million | -5.94% |
| 2017-12-31 | $459.19 Million | -20.18% |
| 2016-12-31 | $575.31 Million | +335039.20% |
| 2015-12-31 | $171.66K | -98.74% |
| 2014-12-31 | $13.59 Million | -- |